Citius Oncology, Inc. (CTOR)
NASDAQ:CTOR
Want to see CTOR full AI Analyst Report?
Top Page
Citius Oncology
(NASDAQ:CTOR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.94
▼(-11.96% Downside)
Action:Reiterated
Date:05/07/26
The score is primarily held back by weak financial performance (pre-revenue, widening losses, and rising cash burn) and limited valuation support (negative P/E, no dividend). Technicals show modest near-term improvement, while corporate events are mixed—commercial progress and new financing are offset by dilution/debt considerations and Nasdaq non-compliance risk.
Positive Factors
Early commercial traction
The December 2025 U.S. launch shows durable uptake signals: sequential orders, repeat purchases and broad payer coverage suggest formulary adoption and clinical acceptance. This creates a foundation for recurring demand and payer negotiations, reducing go-to-market execution risk over the next 2–6 months.
Negative Factors
Pre-revenue with rising cash burn
CTOR remains pre-revenue while cash burn and negative free cash flow have materially increased, pressuring runway. Absent sustained revenue growth, the company will likely require additional financing, creating structural funding risk that can constrain investment in commercialization and R&D over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Early commercial traction
The December 2025 U.S. launch shows durable uptake signals: sequential orders, repeat purchases and broad payer coverage suggest formulary adoption and clinical acceptance. This creates a foundation for recurring demand and payer negotiations, reducing go-to-market execution risk over the next 2–6 months.
Read all positive factors
Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$77.08M
Dividend YieldN/A
Average Volume (3M)107.00K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume95,414
30 Day Avg. Volume106,999
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue14.13
Enterprise Value/Gross Profit17.64
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$4.00Price Target Upside273.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$20.82M
Citius Oncology Business Overview & Revenue Model
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The compa...
How the Company Makes Money
As of publicly available information, CTOR’s revenue-generating commercial operations are null. The company is primarily a development-stage oncology company, so its funding and cash inflows are generally expected to come from non-operating source...
Citius Oncology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.61M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -42.88M | -23.49M | -20.57M | -12.12M | 0.00 |
| Net Income | -42.51M | -24.76M | -21.15M | -12.70M | -10.87M |
Balance Sheet | |||||
| Total Assets | 100.70M | 100.94M | 84.37M | 47.73M | 42.69M |
| Cash, Cash Equivalents and Short-Term Investments | 2.63M | 3.92M | 112.00 | 0.00 | 0.00 |
| Total Debt | 3.80M | 3.80M | 3.80M | 0.00 | 0.00 |
| Total Liabilities | 65.43M | 56.08M | 38.23M | 22.20M | 6.42M |
| Stockholders Equity | 35.27M | 44.87M | 46.14M | 25.54M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -16.86M | -5.49M | 126.35K | -601.30K | -47.97K |
| Operating Cash Flow | -16.86M | -5.49M | 126.35K | -601.30K | -47.97K |
| Investing Cash Flow | -10.86M | -5.75M | -5.00M | -1.32M | -67.32M |
| Financing Cash Flow | 30.36M | 15.17M | 4.87M | 1.66M | 67.66M |
Citius Oncology Technical Analysis
Negative
1.07
Price Trends
0.79
Positive
0.95
Negative
1.28
Negative
Market Momentum
<0.01
Positive
44.58
Neutral
33.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 1.07 is above the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.79, and below the 200-day MA of 1.28, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.58 is Neutral, neither overbought nor oversold. The STOCH value of 33.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.
Citius Oncology Risk Analysis
Citius Oncology disclosed 52 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $27.97B | 21.12 | 7.55% | ― | 2.11% | -7.88% | |
63 Neutral | $3.53B | 2.67 | 29.87% | 4.80% | -2.08% | -67.52% | |
59 Neutral | $6.76B | 15.91 | 7.88% | 1.56% | 8.91% | 129.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $77.08M | ― | -99.47% | ― | ― | ― | |
43 Neutral | $76.14M | -1.51 | 767.26% | ― | ― | ― |
* Healthcare Sector Average
CTOR
Citius Oncology
0.84
-0.07
-7.80%
BIIB
Biogen
193.76
67.95
54.01%
GRFS
Grifols SA
7.98
-0.02
-0.25%
SRXH
SRx Health Solutions
0.13
-0.46
-78.40%
SCLX
Scilex Holding Company
6.11
1.56
34.29%
OGN
Organon
13.43
4.82
55.93%
Citius Oncology Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Citius Oncology Secures New Financing to Support LYMPHIR
Positive
May 6, 2026
On May 5, 2026, Citius Oncology secured up to $36.5 million in combined debt and equity-related capital to support the commercialization of LYMPHIR, its recently launched cutaneous T‑cell lymphoma therapy. The financings are aimed at funding...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Begins First European Expansion of LYMPHIR
Positive
Apr 29, 2026
On April 29, 2026, Citius Oncology announced it had shipped the first international order of LYMPHIR to Europe via a regional distribution partner, expanding access to the CTCL therapy outside the U.S. under Named Patient Programs in select market...
Delistings and Listing ChangesRegulatory Filings and Compliance
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
Negative
Apr 28, 2026
On April 22, 2026, Citius Oncology disclosed that it received a notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering non-compliance with Nasdaq’s listing requireme...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Citius Oncology highlights early LYMPHIR commercial traction, expansion
Positive
Apr 1, 2026
On March 31, 2026, Citius Oncology reported early commercial traction for LYMPHIR (denileukin diftitox-cxdl) in the U.S. following its December 2025 launch for relapsed or refractory cutaneous T-cell lymphoma. The company highlighted sequential or...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
Positive
Mar 10, 2026
On March 10, 2026, Citius Oncology reported positive topline data from a completed investigator-initiated Phase 1 trial led by University of Pittsburgh researchers evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or ...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
Positive
Mar 4, 2026
On March 4, 2026, Citius Oncology reported positive topline safety and efficacy data from an investigator-initiated Phase 1 trial of LYMPHIR administered before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse lar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.